We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
INQOVI 35/100 (Otsuka Australia Pharmaceutical Pty Ltd)
Product name
INQOVI 35/100
Date registered
Evaluation commenced
Decision date
Approval time
123 working days (255)
Active ingredients
cedazuridine; decitabine
Registration type
NCE/NBE
Indication
INQOVI 35/100 (tablet) is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS) intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups, and patients with chronic myelomonocytic leukaemia (CMML).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.